Bumetanide

CAS No:
28395-03-1 Category:
  • #LGM Pharma is a Bumetanide CAS# 28395-03-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 28395-03-1
  • AHFC code: 40:28.1
  • Synonyms: Bumetanida [INN-Spanish] Bumetanidum [INN-Latin]
  • ATC Code: C03CA02
  • Chemical Formula: C12H24N2O4
  • Molecular Weight: 364.416
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00887 (APRD00294)
  • SMILES: CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
  • InChl: MAEIEVLCKWDQJH-UHFFFAOYSA-N
  • PubChem: 2471
  • IUPAC: 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid

Additional Details

Indication:
For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.
Pharmacodynamics:
Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect. Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).
Mode of Action:
Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis.
Metabolism:
45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain.
Toxicity:
Overdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos